(Q36536752)

14 August 2017

1 reference

title

Cost-effectiveness of sirolimus therapy with early cyclosporin withdrawal vs. long-term cyclosporin therapy in Australia (English)

1 reference

14 August 2017

0 references

1 reference

Adam Gordois

1

1 reference

14 August 2017

Michael Nobes

series ordinal

2

1 reference

14 August 2017

Michaela Toohey

series ordinal

3

1 reference

14 August 2017

Graeme Russ

series ordinal

4

1 reference

14 August 2017

language of work or name

1 reference

1 July 2006

1 reference

14 August 2017

published in

Clinical Transplantation

1 reference

14 August 2017

volume

20

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

526-536

1 reference

The natural history of chronic allograft nephropathy

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00518.X

Associations between use of cyclosporine-sparing agents and outcome in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00518.X

Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00518.X

Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00518.X

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00518.X

A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00518.X

Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00518.X

Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00518.X

Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00518.X

Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00518.X

Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00518.X

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00518.X

Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00518.X

Utility approach to measuring health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00518.X

10.1111/J.1399-0012.2006.00518.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference